Cancer Research Meeting Calendar Advances in Breast Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Trinei, M.
Right arrow Articles by Falini, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Trinei, M.
Right arrow Articles by Falini, B.
[Cancer Research 60, 793-798, February 15, 2000]
© 2000 American Association for Cancer Research

Advances in Brief

A New Variant Anaplastic Lymphoma Kinase (ALK)-Fusion Protein (ATIC-ALK) in a Case of ALK-positive Anaplastic Large Cell Lymphoma1

Mirella Trinei, Luisa Lanfrancone, Elias Campo, Karen Pulford, David Y. Mason, Pier-Giuseppe Pelicci2 and Brunangelo Falini

Department of Experimental Oncology, Istituto Europeo di Oncologia, 20141 Milan, Italy [M. T., L. L., P-G. P.]; Department of Pathology, University of Barcelona, Barcelona, Spain [E. C.]; LRF Immunodiagnostics Unit, John Radcliffe Hospital, Oxford, United Kingdom [K. P., D. Y. M.]; and Institute of Hematology, University of Perugia, 06100 Perugia, Italy [B. F.]

Anaplastic lymphoma kinase (ALK)-positive lymphomas ("ALKomas") constitute a distinct molecular and clinicopathological entity within the heterogeneous group of CD30-positive large cell lymphomas. In 80–85% of cases tumor cells express a Mr 80,000 hybrid protein comprising the nucleolar phosphoprotein nucleophosmin (NPM) and the ALK. We report here the cloning and expression of a novel ALK-fusion protein from an ALK-positive lymphoma. This case was selected for molecular investigation because of (a) the absence of NPM-ALK transcripts; (b) the atypical staining patterns for ALK (cytoplasm-restricted) and for NPM (nucleus-restricted); and (c) the presence of a Mr 96,000 ALK-protein differing in size from NPM-ALK. Nucleotide sequence analysis of ALK transcripts isolated by 5'-rapid amplification of cDNA ends revealed a chimeric mRNA corresponding to an ATIC-ALK in-frame fusion. ATIC is a bifunctional enzyme (5-aminoimidazole-4-carboxamide ribonucleotide transformylase and IMP cyclohydrolase enzymatic activities) that catalyzes the penultimate and final enzymatic activities of the purine nucleotide synthesis pathway. Expression of full-length ATIC-ALK cDNA in mouse fibroblasts revealed that the fusion protein (a) possesses constitutive tyrosine kinase activity; (b) forms stable complexes with the signaling proteins Grb2 and Shc; (c) induces tyrosine-phosphorylation of Shc; and (d) provokes oncogenic transformation. These findings point to fusion with ATIC as an alternative mechanism of ALK activation.




This article has been cited by other articles:


Home page
 BloodHome page
F. E. Boccalatte, C. Voena, C. Riganti, A. Bosia, L. D'Amico, L. Riera, M. Cheng, B. Ruggeri, O. N. Jensen, V. L. Goss, et al.
The enzymatic activity of 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase is enhanced by NPM-ALK: new insights in ALK-mediated pathogenesis and the treatment of ALCL
Blood, March 19, 2009; 113(12): 2776 - 2790.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
B C Gleason and J L Hornick
Inflammatory myofibroblastic tumours: where are we now?
J. Clin. Pathol., April 1, 2008; 61(4): 428 - 437.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Fawal, F. Armstrong, S. Ollier, H. Dupont, C. Touriol, B. Monsarrat, G. Delsol, B. Payrastre, and D. Morello
A "liaison dangereuse" between AUF1/hnRNPD and the oncogenic tyrosine kinase NPM-ALK
Blood, October 15, 2006; 108(8): 2780 - 2788.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. ProteomicsHome page
M. S. Lim and K. S. J. Elenitoba-Johnson
Mass Spectrometry-based Proteomic Studies of Human Anaplastic Large Cell Lymphoma
Mol. Cell. Proteomics, October 1, 2006; 5(10): 1787 - 1798.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. A. Rizvi, A. M. Evens, M. S. Tallman, B. P. Nelson, and S. T. Rosen
T-cell non-Hodgkin lymphoma
Blood, February 15, 2006; 107(4): 1255 - 1264.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
R. D. Gascoyne, L. Lamant, J. I. Martin-Subero, V. S. Lestou, N. L. Harris, H.-K. Muller-Hermelink, J. F. Seymour, L. J. Campbell, D. E. Horsman, I. Auvigne, et al.
ALK-positive diffuse large B-cell lymphoma is associated with Clathrin-ALK rearrangements: report of 6 cases
Blood, October 1, 2003; 102(7): 2568 - 2573.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
T. Ouyang, R.-Y. Bai, F. Bassermann, C. von Klitzing, S. Klumpen, C. Miething, S. W. Morris, C. Peschel, and J. Duyster
Identification and Characterization of a Nuclear Interacting Partner of Anaplastic Lymphoma Kinase (NIPA)
J. Biol. Chem., August 8, 2003; 278(32): 30028 - 30036.
[Abstract] [Full Text] [PDF]

Home page
 J. Mol. Diagn.Home page
N. S. Reading, S. D. Jenson, J. K. Smith, M. S. Lim, and K. S. J. Elenitoba-Johnson
5'-(RACE) Identification of Rare ALK Fusion Partner in Anaplastic Large Cell Lymphoma
J. Mol. Diagn., May 1, 2003; 5(2): 136 - 140.
[Full Text] [PDF]

Home page
 JCOHome page
J. L. Kutok and J. C. Aster
Molecular Biology of Anaplastic Lymphoma Kinase-Positive Anaplastic Large-Cell Lymphoma
J. Clin. Oncol., September 1, 2002; 20(17): 3691 - 3702.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
G. Piccinini, R. Bacchiocchi, M. Serresi, C. Vivani, S. Rossetti, C. Gennaretti, D. Carbonari, and F. Fazioli
A Ligand-inducible Epidermal Growth Factor Receptor/Anaplastic Lymphoma Kinase Chimera Promotes Mitogenesis and Transforming Properties in 3T3 Cells
J. Biol. Chem., June 14, 2002; 277(25): 22231 - 22239.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
L. Hernandez, S. Bea, B. Bellosillo, M. Pinyol, B. Falini, A. Carbone, G. Ott, A. Rosenwald, A. Fernandez, K. Pulford, et al.
Diversity of Genomic Breakpoints in TFG-ALK Translocations in Anaplastic Large Cell Lymphomas : Identification of a New TFG-ALKXL Chimeric Gene with Transforming Activity
Am. J. Pathol., April 1, 2002; 160(4): 1487 - 1494.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
L. Passoni, A. Scardino, C. Bertazzoli, B. Gallo, A. M. L. Coluccia, F. A. Lemonnier, K. Kosmatopoulos, and C. Gambacorti-Passerini
ALK as a novel lymphoma-associated tumor antigen: identification of 2 HLA-A2.1-restricted CD8+ T-cell epitopes
Blood, March 15, 2002; 99(6): 2100 - 2106.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
B. Falini and D. Y. Mason
Proteins encoded by genes involved in chromosomal alterations in lymphoma and leukemia: clinical value of their detection by immunocytochemistry
Blood, January 15, 2002; 99(2): 409 - 426.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
Q. Zhang, P. N. Raghunath, L. Xue, M. Majewski, D. F. Carpentieri, N. Odum, S. Morris, T. Skorski, and M. A. Wasik
Multilevel Dysregulation of STAT3 Activation in Anaplastic Lymphoma Kinase-Positive T/Null-Cell Lymphoma
J. Immunol., January 1, 2002; 168(1): 466 - 474.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. J. Meech, L. McGavran, L. F. Odom, X. Liang, L. Meltesen, J. Gump, Q. Wei, S. Carlsen, and S. P. Hunger
Unusual childhood extramedullary hematologic malignancy with natural killer cell properties that contains tropomyosin 4-anaplastic lymphoma kinase gene fusion
Blood, August 15, 2001; 98(4): 1209 - 1216.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
B. Maes, V. Vanhentenrijk, I. Wlodarska, J. Cools, B. Peeters, P. Marynen, and C. De Wolf-Peeters
The NPM-ALK and the ATIC-ALK Fusion Genes Can Be Detected in Non-Neoplastic Cells
Am. J. Pathol., June 1, 2001; 158(6): 2185 - 2193.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
R.-Y. Bai, T. Ouyang, C. Miething, S. W. Morris, C. Peschel, and J. Duyster
Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway
Blood, December 15, 2000; 96(13): 4319 - 4327.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
H. Stein, H.-D. Foss, H. Durkop, T. Marafioti, G. Delsol, K. Pulford, S. Pileri, and B. Falini
CD30+ anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features
Blood, December 1, 2000; 96(12): 3681 - 3695.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
R. Suzuki, Y. Kagami, K. Takeuchi, M. Kami, M. Okamoto, R. Ichinohasama, N. Mori, M. Kojima, T. Yoshino, H. Yamabe, et al.
Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T/null cell phenotype
Blood, November 1, 2000; 96(9): 2993 - 3000.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
M. Ladanyi
Aberrant ALK Tyrosine Kinase Signaling : Different Cellular Lineages, Common Oncogenic Mechanisms?
Am. J. Pathol., August 1, 2000; 157(2): 341 - 345.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2000 by the American Association for Cancer Research.